These results strongly suggest that PTEN is a critical tumor suppressor in the pathogenesis of SCLC and provide a rationale for treating patients with PTEN mutations with inhibitors of its downstream effectors, PI3K and AKT. Here, PIK3CA is linked to neoplasm.